MX362089B - Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos. - Google Patents

Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.

Info

Publication number
MX362089B
MX362089B MX2014007131A MX2014007131A MX362089B MX 362089 B MX362089 B MX 362089B MX 2014007131 A MX2014007131 A MX 2014007131A MX 2014007131 A MX2014007131 A MX 2014007131A MX 362089 B MX362089 B MX 362089B
Authority
MX
Mexico
Prior art keywords
nanoparticles
metallic
hafnium oxide
preparation
relates
Prior art date
Application number
MX2014007131A
Other languages
English (en)
Other versions
MX2014007131A (es
Inventor
Pottier Agnés
Levy Laurent
Meyre Marie-Edith
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of MX2014007131A publication Critical patent/MX2014007131A/es
Publication of MX362089B publication Critical patent/MX362089B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/242—Gold; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1241—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins
    • A61K51/1244—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules particles, powders, lyophilizates, adsorbates, e.g. polymers or resins for adsorption or ion-exchange resins microparticles or nanoparticles, e.g. polymeric nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pathology (AREA)
  • Dispersion Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Powder Metallurgy (AREA)

Abstract

La presente invención se relaciona con nanopartículas novedosas las cuales se pueden utilizar ventajosamente en el sector salud como diagnóstico y/o agentes terapéuticos. Las nanopartículas de la invención comprenden un material metálico al menos parcialmente recubierto con un material de óxido de hafnio o incorporado en el mismo. Cuando se compararon a productos existentes, estas nanopartículas ofrecen un beneficio extraordinario sobre el cociente de riesgo. Específicamente, estas nanopartículas aumentan la eficiencia de nanopartículas metálicas conocidas. De hecho, conservan las propiedades intrínsecas del metal y son ahora además utilizables de manera segura en un mamífero, en particular en un ser humano. La invención también se relaciona a métodos para producir las nanopartículas, a composiciones que contienen las mismas, y al usos de las mismas.
MX2014007131A 2011-12-16 2012-12-17 Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos. MX362089B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161576437P 2011-12-16 2011-12-16
EP11193968 2011-12-16
PCT/EP2012/075731 WO2013087920A1 (en) 2011-12-16 2012-12-17 Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof

Publications (2)

Publication Number Publication Date
MX2014007131A MX2014007131A (es) 2014-09-04
MX362089B true MX362089B (es) 2019-01-07

Family

ID=48611880

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014007131A MX362089B (es) 2011-12-16 2012-12-17 Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.

Country Status (16)

Country Link
US (1) US10945965B2 (es)
EP (1) EP2790682B1 (es)
JP (1) JP6042450B2 (es)
KR (1) KR102025743B1 (es)
CN (1) CN104093401B (es)
AU (1) AU2012351537B2 (es)
BR (1) BR112014014412A2 (es)
CA (1) CA2857260C (es)
EA (1) EA029635B1 (es)
HK (1) HK1203353A1 (es)
IL (1) IL233035B (es)
MA (1) MA35851B1 (es)
MX (1) MX362089B (es)
PL (1) PL2790682T3 (es)
SG (1) SG11201403096VA (es)
WO (1) WO2013087920A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3494974B1 (en) 2011-07-08 2023-10-18 The University of North Carolina at Chapel Hill Metal bisphosphonate nanoparticles for anti-cancer therapy and imaging and for treating bone disorders
KR102025743B1 (ko) 2011-12-16 2019-09-26 나노비오?스 금속성 및 산화하프늄 소재를 포함하는 나노입자, 이의 제조 및 용도
KR102225239B1 (ko) * 2013-01-25 2021-03-09 나노비오?笭? 암 치료용 이온화 방사선과 조합된 무기 나노입자 조성물
KR20160027009A (ko) * 2013-06-20 2016-03-09 나노비오띡스 의학적 진단에 사용되는 조성물 및 방법
US10806694B2 (en) * 2014-10-14 2020-10-20 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, radiodynamic therapy, chemotherapy, immunotherapy, and any combination thereof
US10206871B2 (en) 2014-10-14 2019-02-19 The University Of Chicago Nanoparticles for photodynamic therapy, X-ray induced photodynamic therapy, radiotherapy, chemotherapy, immunotherapy, and any combination thereof
HK1246160A1 (zh) * 2015-05-28 2018-09-07 Nanobiotix 用作治疗性疫苗的纳米粒子
US11389536B2 (en) * 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
US9607952B1 (en) * 2015-10-30 2017-03-28 International Business Machines Corporation High-z oxide nanoparticles embedded in semiconductor package
EP3439666A4 (en) 2016-05-20 2019-12-11 The University of Chicago NANOPARTICLES FOR CHEMOTHERAPY, TARGETED THERAPY, PHOTODYNAMIC THERAPY, IMMUNOTHERAPY AND ALL COMBINATIONS THEREOF
JP7766899B2 (ja) * 2016-12-21 2025-11-11 ナノビオティックス 神経障害を処置するのに使用するためのナノ粒子
EP3638367A4 (en) 2017-08-02 2021-07-21 The University of Chicago NANOMETRIC ORGANOMETALLIC AND NANOPLAQUE ORGANOMETALLIC LAYERS FOR X-RAY INDUCED PHOTODYNAMIC THERAPY, RADIOTHERAPY, RADIODYNAMIC THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND ANY COMBINATION OF THESE
JP7116563B2 (ja) * 2018-03-16 2022-08-10 株式会社日本触媒 複合粒子
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
KR20230038659A (ko) * 2020-05-26 2023-03-21 나노비오띡스 나노 입자, 전리 방사선 및 그의 혁신적인 치료용 조합
CN112675305B (zh) * 2021-01-22 2023-05-23 中国科学院深圳先进技术研究院 用于肿瘤治疗的双亲性分子自组装纳米药物及制备方法和用途
CN116917009A (zh) 2021-02-19 2023-10-20 美国迈胜医疗系统有限公司 用于粒子治疗系统的机架
EP4633676A1 (en) 2022-12-12 2025-10-22 Nanobiotix Novel metal oxide nanoparticles and compositions thereof for use as radioenhancers or for visualizing biological tissue

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4280918A (en) 1980-03-10 1981-07-28 International Business Machines Corporation Magnetic particle dispersions
US4672040A (en) 1983-05-12 1987-06-09 Advanced Magnetics, Inc. Magnetic particles for use in separations
US4770183A (en) 1986-07-03 1988-09-13 Advanced Magnetics Incorporated Biologically degradable superparamagnetic particles for use as nuclear magnetic resonance imaging agents
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US6099457A (en) * 1990-08-13 2000-08-08 Endotech, Inc. Endocurietherapy
US5370901A (en) 1991-02-15 1994-12-06 Bracco International B.V. Compositions for increasing the image contrast in diagnostic investigations of the digestive tract of patients
JPH05209072A (ja) * 1992-01-29 1993-08-20 Japan Synthetic Rubber Co Ltd 基材の表面処理方法
WO1993026019A1 (en) 1992-06-08 1993-12-23 Molecular Bioquest, Inc. Preparation of controlled size inorganic particles for use in separations, as magnetic molecular switches, and as inorganic liposomes for medical applications
WO1994002068A1 (en) 1992-07-21 1994-02-03 The General Hospital Corporation System of drug delivery to the lymphatic tissues
US5395619A (en) 1993-03-03 1995-03-07 Liposome Technology, Inc. Lipid-polymer conjugates and liposomes
DE19716732C2 (de) 1997-03-07 1999-03-25 Max Delbrueck Centrum Spezifische Magnetosomen, Verfahren zu ihrer Herstellung und ihre Verwendung
JP3902794B2 (ja) 1997-03-07 2007-04-11 マックス−デルブルック−セントラム フュア モレクラーレ メディシン 特異的磁気体、その製造方法及び使用
DE19726282A1 (de) 1997-06-20 1998-12-24 Inst Neue Mat Gemein Gmbh Nanoskalige Teilchen mit einem von mindestens zwei Schalen umgebenen eisenoxid-haltigen Kern
US6200598B1 (en) 1998-06-18 2001-03-13 Duke University Temperature-sensitive liposomal formulation
US6726925B1 (en) 1998-06-18 2004-04-27 Duke University Temperature-sensitive liposomal formulation
US6645464B1 (en) * 1998-07-30 2003-11-11 James F. Hainfeld Loading metal particles into cell membrane vesicles and metal particular use for imaging and therapy
WO2001037721A2 (en) 1999-11-22 2001-05-31 The Research Foundation Of State University Of New York Magnetic nanoparticles for selective therapy
EP1263447B1 (en) 2000-02-08 2013-06-26 Rice University Optically-active nanoparticles for use in therapeutic and diagnostic methods
AU2002259107B2 (en) 2001-04-30 2006-10-26 Cytimmune Sciences, Inc. Colloidal metal compositions and methods
DE10154016B4 (de) 2001-10-26 2004-02-12 Berlin Heart Ag Magnetflüssigkeit und Verfahren zur ihrer Herstellung
AU2002351240A1 (en) * 2002-03-08 2003-09-22 James Hainfeld Gold nanoparticles used for x-rays imaging
US7769423B2 (en) 2002-09-11 2010-08-03 Duke University MRI imageable liposomes for the evaluation of treatment efficacy, thermal distribution, and demonstration of dose painting
US20030125283A1 (en) 2002-09-16 2003-07-03 Gatenby Robert A. Therapy of proliferative disorders by direct irradiation of cell nuclei with tritiated nuclear targetting agents
US7235228B2 (en) 2003-04-15 2007-06-26 The United States Of America As Represented By The Secretary Of The Navy Fluorescent-magnetic nanoparticles with core-shell structure
US20050084869A1 (en) 2003-10-20 2005-04-21 Sung Hyun Kim Novel composition and methods for the diagnosis of lung cancer
CN1882364A (zh) 2003-11-17 2006-12-20 皇家飞利浦电子股份有限公司 用于医学成像技术的造影剂及其应用
WO2005063305A1 (en) 2003-12-22 2005-07-14 Bracco Research Sa Gas-filled microvesicle assembly for contrast imaging
JP4895151B2 (ja) * 2004-02-27 2012-03-14 日立金属株式会社 鉄系ナノサイズ粒子およびその製造方法
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20050260137A1 (en) 2004-05-18 2005-11-24 General Electric Company Contrast agents for magnetic resonance imaging
US20070031337A1 (en) 2004-06-22 2007-02-08 Reinhard Schulte Nanoparticle enhanced proton computed tomography and proton therapy
GB2415374A (en) 2004-06-25 2005-12-28 Leuven K U Res & Dev Targeted delivery of biologically active substances using iron oxide/gold core-shell nanoparticles
WO2006037081A2 (en) * 2004-09-28 2006-04-06 The Regents Of The University Of California Nanoparticle radiosensitizers
AU2005303251A1 (en) 2004-11-10 2006-05-18 Konica Minolta Medical & Graphic, Inc. Pharmaceutical preparation containing covered magnetic particles, manufacturing method thereof and diagnostic therapeutic system
US20070092927A1 (en) 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
US20090304587A1 (en) 2005-11-01 2009-12-10 Yissum Research Development Company Of The Hebrew University Of Jerusalem Biodegradable composite for internal local radiotherapy
US20070098641A1 (en) 2005-11-02 2007-05-03 General Electric Company Nanoparticle-based imaging agents for X-ray/computed tomography
KR100745744B1 (ko) * 2005-11-11 2007-08-02 삼성전기주식회사 나노 입자 코팅 방법
WO2007122956A1 (ja) 2006-03-24 2007-11-01 Toto Ltd. 酸化チタン複合体粒子、その分散液、およびそれらの製造方法
JP2009536151A (ja) 2006-03-30 2009-10-08 富士フイルム株式会社 ナノ粒子
EP1852107A1 (en) 2006-04-19 2007-11-07 Nanobiotix Magnetic nanoparticles compositions and uses thereof
EP2040752A2 (en) 2006-07-10 2009-04-01 Philips Intellectual Property & Standards GmbH Core-shell nanoparticles for thearapy and imaging purposes
DE102006041495A1 (de) 2006-08-29 2008-03-20 Friedrich-Schiller-Universität Jena Substanzgemisch zur lokalen Deposition von Magnetpartikeln in einem Medium, insbesondere in tumorbefallenem organischem Gewebe, sowie Applikationskit zur Verabreichung
NO329127B1 (no) 2006-09-12 2010-08-30 Epitarget As Sporbart partikulaert materiale for legemiddelavlevering omfattende et matriseeller membranmateriale, et legemiddel, og et T1- og et T2*- magnetisk resonanskontrastmiddel
NO20064315L (no) 2006-09-22 2008-03-24 Epitarget As T1 MRI-sporbare medikamentavleveringspartikler and anvendelse derav
EP1920784A1 (en) 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging
US20090004258A1 (en) 2007-06-27 2009-01-01 National Health Research Institutes Drug Release from Thermosensitive Liposomes by Applying an Alternative Magnetic Field
JP2009067613A (ja) 2007-09-11 2009-04-02 Fujifilm Corp コア−シェル型金属酸化物微粒子及びその製造方法
US20120176016A1 (en) * 2007-09-28 2012-07-12 General Electric Company Core-shell particulates, articles, and method of making
FR2922106B1 (fr) 2007-10-16 2011-07-01 Univ Claude Bernard Lyon Utilisation de nanoparticules a base de lanthanides comme agents radiosensibilisants.
EP2067485A1 (en) 2007-12-07 2009-06-10 Koninklijke Philips Electronics N.V. Drug carrier providing MRI contrast enhancement
EP2231765A2 (en) 2007-12-21 2010-09-29 University Of Guelph Polysaccharide nanoparticles
WO2009091597A2 (en) 2008-01-16 2009-07-23 Nanospectra Biosciences, Inc. Treatments of disease or disorders using nanoparticles for focused hyperthermia to increase therapy efficacy
DE102008008522A1 (de) 2008-02-11 2009-08-13 Magforce Nanotechnologies Ag Implantierbare Nanopartikel-enthaltende Produkte
WO2009142754A1 (en) 2008-05-22 2009-11-26 Goverment Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dendritic conjugates and methods of use
EP2130553A1 (en) 2008-06-05 2009-12-09 Nanobiotix Inorganic nanoparticles of high density to destroy cells in-vivo
GB0811300D0 (en) * 2008-06-19 2008-07-30 Syngenta Participations Ag Methods of controlling neonicotinoid resistant insects
WO2010048623A2 (en) 2008-10-26 2010-04-29 Board Of Regents, The University Of Texas Systems Medical and imaging nanoclusters
EP2275137A1 (en) 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
EP2305310A1 (en) 2009-09-25 2011-04-06 Asociación Centro de Investigación Cooperativa en Biomateriales - CIC biomaGUNE Gold -coated magnetic glyconanoparticles functionalised with proteins for use as diagnostic and therapeutic agents
GB0921596D0 (en) 2009-12-09 2010-01-27 Isis Innovation Particles for the treatment of cancer in combination with radiotherapy
JP5649137B2 (ja) 2010-02-17 2015-01-07 国立大学法人神戸大学 放射線治療剤
WO2011127061A1 (en) 2010-04-05 2011-10-13 Nanospectra Biosciences, Inc. Enhancement of radiation therapy by targeted high-z nanoparticles
GB201009455D0 (en) 2010-06-04 2010-07-21 King S College London Nanoparticles and their uses in molecular imaging
PL2670394T3 (pl) 2011-01-31 2019-03-29 Nanobiotix Układy do dostarczania nanocząstek, ich otrzymywanie i zastosowania
US20140227343A1 (en) 2011-01-31 2014-08-14 Centre National De La Recherche Scientifique Method of monitoring the release from liposomes of a product of interest using superparamagnetic nanoparticles
KR102025743B1 (ko) 2011-12-16 2019-09-26 나노비오?스 금속성 및 산화하프늄 소재를 포함하는 나노입자, 이의 제조 및 용도
KR102225239B1 (ko) 2013-01-25 2021-03-09 나노비오?笭? 암 치료용 이온화 방사선과 조합된 무기 나노입자 조성물
US20140219926A1 (en) 2013-02-01 2014-08-07 The Trustees Of Dartmouth College Biodegradable Iron Oxide Nanoparticle Gel for Tumor Bed Therapy
UA116380C2 (uk) 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
EP3010552B1 (en) 2013-06-20 2019-04-17 Nanobiotix Compositions for use in oncology
KR20160027009A (ko) 2013-06-20 2016-03-09 나노비오띡스 의학적 진단에 사용되는 조성물 및 방법
EP2886128A1 (en) 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof

Also Published As

Publication number Publication date
WO2013087920A1 (en) 2013-06-20
HK1203353A1 (en) 2015-10-30
CN104093401B (zh) 2018-06-29
IL233035A0 (en) 2014-07-31
MA35851B1 (fr) 2014-12-01
SG11201403096VA (en) 2014-07-30
MX2014007131A (es) 2014-09-04
US10945965B2 (en) 2021-03-16
EP2790682B1 (en) 2019-03-20
EA029635B1 (ru) 2018-04-30
KR20140108685A (ko) 2014-09-12
BR112014014412A2 (pt) 2017-06-13
PL2790682T3 (pl) 2019-08-30
EP2790682A1 (en) 2014-10-22
JP6042450B2 (ja) 2016-12-14
JP2015509079A (ja) 2015-03-26
IL233035B (en) 2018-02-28
CN104093401A (zh) 2014-10-08
AU2012351537B2 (en) 2017-03-02
CA2857260C (en) 2019-10-15
AU2012351537A1 (en) 2014-07-24
CA2857260A1 (en) 2013-06-20
KR102025743B1 (ko) 2019-09-26
EA201491199A1 (ru) 2014-11-28
NZ625848A (en) 2015-04-24
US20140335015A1 (en) 2014-11-13

Similar Documents

Publication Publication Date Title
MX362089B (es) Nanopartículas que comprenden materiales metálicos y óxido de hafnio, preparación y usos de los mismos.
IL272313A (en) Intravascular delivery of nanoparticle preparations and their uses
WO2010091262A8 (en) Chimeric newcastle disease viruses and uses thereof
MY164356A (en) Substituted 5-fluoro-1h-pyrazolopyridines and their use
CA2863681A1 (en) Topical use of a skin-commensal prebiotic agent and compositions containing the same
WO2012177757A3 (en) Personal care compositions comprising shaped abrasive particles
WO2014062720A3 (en) Methods of treating cancer
IL236892A0 (en) A preparation containing two engineered antibodies to allow reduced or increased effector activity
IL219876A (en) Antibodies against human 1h-7b or its fragment, preparations containing them and their use in the preparation of drugs
IL231536A (en) Indazole-3-carboxamides, pharmaceuticals containing them and their use in the treatment of diseases
IN2015DN00392A (es)
WO2012065022A3 (en) Spiro-oxindole mdm2 antagonists
WO2012112410A3 (en) Micronized placental tissue compositions and methods for making and using the same
MX2019000225A (es) Composiciones y metodos para el tratamiento de enfermedades autoinmunes y otras enfermedades.
IL226475A0 (en) Preparations and methods for the treatment of wide-ranging clinical applications
PT2555763E (pt) Composições inibidoras virais para utilização terapêutica in vivo que compreendem uma combinação de (-)-carvona, (+)- carnona, geraniol e um componente de óleo essencial adicional
IL248880B (en) Preparations containing r-g-cysteic acid peptides and their uses for the treatment of eye diseases
WO2012121528A3 (en) Magnetic nanocomposite specific for thyroid cancer and use thereof
ZA201205432B (en) Compositions and methods for the diagnosis and treatment of tumor
GB2503066B (en) Combination pharmaceutical composition and methods of treating and preventing the infectious diseases
PL2768936T3 (pl) Preparaty, ich zastosowanie jako środków do zmywania naczyń lub do wytwarzania środków do zmywania naczyń i ich wytwarzanie
WO2012095399A3 (en) Personal care compositions
WO2012098562A3 (en) Liquid oral compositions of lanthanum salts
EP3150632A3 (en) Anti-ricin antibodies and uses thereof
EP3456837A3 (en) Decorin compositions and use thereof

Legal Events

Date Code Title Description
FG Grant or registration